search
Back to results

CO2-Angiography-Study to Evaluate Diagnostic and Safety to Patients With Peripher Arterial Stenotic or Occlusive Disease. (ACDA-RCT)

Primary Purpose

Peripheral Arterial Occlusive Disease

Status
Completed
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
Angiography
Sponsored by
Jena University Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Peripheral Arterial Occlusive Disease focused on measuring CO2, angiography, peripheral occlusion disease, contrast medium, carbon dioxid enhanced angiography

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age > 18 years
  • Male, female
  • Patients with indication for percutaneous transluminal angioplasty of iliacal- or femoropopliteal arteries

Exclusion Criteria:

  • Children and adolescents < 18 years
  • Diagnostic angiography, CT- or MRI-angiography during the past 3 months
  • Patients with reduced renal function (S-creatinine > 1,2 mg/dl)
  • Incapacitated patients
  • Severe COPD
  • Known atrium- or ventricular septal defect with right-left-shunt
  • Current participation in other interventional studies

Sites / Locations

  • University Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

CO2 first/ iodine CM second

iodine CM first/ CO2 second

Arm Description

CO2-enhanced angiography

iodine contrast media-enhanced angiography

Outcomes

Primary Outcome Measures

Degree of stenosis
Calculation of maximum grade of stenosis

Secondary Outcome Measures

Image quality
Image quality assessed by blinded radiologists who did not perform the angiographic intervention.
occurence of adverse events
Complications documted within 24 hours and pain scale during intervention

Full Information

First Posted
July 17, 2017
Last Updated
October 19, 2022
Sponsor
Jena University Hospital
Collaborators
AngioDroid s.r.l., Bologna (Italy)
search

1. Study Identification

Unique Protocol Identification Number
NCT05590182
Brief Title
CO2-Angiography-Study to Evaluate Diagnostic and Safety to Patients With Peripher Arterial Stenotic or Occlusive Disease.
Acronym
ACDA-RCT
Official Title
Randomized-Controlled Study to Evaluate the Diagnostic Quality and Safety of Automated Carbon Dioxide Angiography (ACDA) With a Robot-supported Angiography System in Combination With a CO2-Injector System in Patients With Peripheral Arterial Occlusive Disease
Study Type
Interventional

2. Study Status

Record Verification Date
October 2022
Overall Recruitment Status
Completed
Study Start Date
September 1, 2017 (Actual)
Primary Completion Date
July 1, 2021 (Actual)
Study Completion Date
October 1, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Jena University Hospital
Collaborators
AngioDroid s.r.l., Bologna (Italy)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This randomized study focuses on the diagnostic quality and safety of CO2 application as contrast medium through an innovative injector of AngioDroid in angiography interventions in patients with peripheral arterial occlusive diseases.
Detailed Description
CO2-angiography was used as an intra-arterial contrast agent since the 1970s particularly in patients who were hypersensitive to iodinated contrast material or whose renal function was compromised. It is in fact an effective and low-risk alternative to iodine-enhanced conventional angiography because it is not associated with nephrotoxicity or allergic reactions. The image quality influencing the diagnostic validity seems to be a restriction. Now, with the availability of high-resolution DSA and a reliable gas delivery system, CO2 angiography is more and more widely used for vascular imaging and endovascular procedures. Our study will specifically examine the image quality and safety of carbon dioxide gas as intra-arterial contrast agent using the innovative Artis Zeego Q angiography-system of Siemens Healthineers with the automated CO2-injection system of Angiodroid.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Peripheral Arterial Occlusive Disease
Keywords
CO2, angiography, peripheral occlusion disease, contrast medium, carbon dioxid enhanced angiography

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
The randomization that allocates the patient either in the study arm (CO2) or in the control arm (iodine-CM) will occur right before angiography. Stenosis graduation and length will be measured after diagnostic angiography and before intervention. The interventional angiography will be conducted with the opposed contrast media used for diagnostic angiography. If contrast media containing iodine was used for diagnostic angiography, CO2 must be used for interventional angiography and if CO2 was applied for diagnostic angiography, contrast media containing iodine must be used for interventional angiography. The calculated values through the software-quantification-tool, including also a final sequence of the distal outflow with the same contrast media used during intervention, are be compared and statistically analyzed.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
50 (Actual)

8. Arms, Groups, and Interventions

Arm Title
CO2 first/ iodine CM second
Arm Type
Active Comparator
Arm Description
CO2-enhanced angiography
Arm Title
iodine CM first/ CO2 second
Arm Type
Active Comparator
Arm Description
iodine contrast media-enhanced angiography
Intervention Type
Device
Intervention Name(s)
Angiography
Intervention Description
Randomization either in the study arm (CO2) or in the control arm (iodine-CM) occurs right before angiography. Stenosis graduation and length are measured after diagnostic angiography and before intervention. The calculated values through the software-quantification-tool, including also a final sequence of the distal outflow with the same contrast media used during intervention, are be compared and statistically analyzed. A pain protocol to the current pain-situation is led by the present medical-laboratory assistant after administration of CO2 and iodine-CM during intervention.
Primary Outcome Measure Information:
Title
Degree of stenosis
Description
Calculation of maximum grade of stenosis
Time Frame
during intervention
Secondary Outcome Measure Information:
Title
Image quality
Description
Image quality assessed by blinded radiologists who did not perform the angiographic intervention.
Time Frame
2 weeks
Title
occurence of adverse events
Description
Complications documted within 24 hours and pain scale during intervention
Time Frame
24 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age > 18 years Male, female Patients with indication for percutaneous transluminal angioplasty of iliacal- or femoropopliteal arteries Exclusion Criteria: Children and adolescents < 18 years Diagnostic angiography, CT- or MRI-angiography during the past 3 months Patients with reduced renal function (S-creatinine > 1,2 mg/dl) Incapacitated patients Severe COPD Known atrium- or ventricular septal defect with right-left-shunt Current participation in other interventional studies
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ulf Teichgräber, Prof. Dr. med.
Organizational Affiliation
University Hospital Jena, Radiology Department, Germany
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Hospital
City
Jena
State/Province
Thuringia
ZIP/Postal Code
07747
Country
Germany

12. IPD Sharing Statement

Learn more about this trial

CO2-Angiography-Study to Evaluate Diagnostic and Safety to Patients With Peripher Arterial Stenotic or Occlusive Disease.

We'll reach out to this number within 24 hrs